Eicosanoid biosynthesis in human cardiovascular disease.

[1]  L Roy,et al.  Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.

[2]  G. FitzGerald,et al.  11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[3]  G. FitzGerald,et al.  Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. , 1986, Circulation.

[4]  G. FitzGerald,et al.  Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. , 1986, Analytical biochemistry.

[5]  G. FitzGerald,et al.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. , 1986, British medical journal.

[6]  G. FitzGerald,et al.  Estimated rate of thromboxane secretion into the circulation of normal humans. , 1986, The Journal of clinical investigation.

[7]  V. Fuster,et al.  Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. , 1985, Journal of the American College of Cardiology.

[8]  D. Sackett,et al.  Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. , 1985, The New England journal of medicine.

[9]  W. C. Still,et al.  Synthesis and structure of the platelet aggregation factor thromboxane A2 , 1985, Nature.

[10]  E. Falk.  Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. , 1985, Circulation.

[11]  R. Abbate,et al.  Abnormal cardiocoronary thromboxane A2 production in patients with unstable angina. , 1985, American heart journal.

[12]  G. FitzGerald,et al.  Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. , 1985, Circulation.

[13]  G. FitzGerald,et al.  Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing , 1985, Clinical pharmacology and therapeutics.

[14]  G. FitzGerald,et al.  Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. , 1984, The New England journal of medicine.

[15]  L. Fleisher,et al.  Effect of heparin bonding on catheter-induced fibrin formation and platelet activation. , 1984, Circulation.

[16]  S. Shak,et al.  Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels. , 1984, The Journal of clinical investigation.

[17]  M J Davies,et al.  Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. , 1984, The New England journal of medicine.

[18]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[19]  M. Gerritsen,et al.  Arachidonic acid and prostaglandin endoperoxide metabolism in isolated rabbit and coronary microvessels and isolated and cultivated coronary microvessel endothelial cells. , 1983, The Journal of clinical investigation.

[20]  M. LeWinter,et al.  Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. , 1983, The New England journal of medicine.

[21]  Vlasses Ph,et al.  Plasma platelet products and exercise-induced myocardial ischemia. , 1983 .

[22]  G. Minno,et al.  Monitoring the entry of new platelets into the circulation after ingestion of aspirin. , 1983, Blood.

[23]  G. FitzGerald,et al.  Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. , 1983, Circulation.

[24]  B. Weksler,et al.  Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. , 1983, The New England journal of medicine.

[25]  G. FitzGerald,et al.  Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.

[26]  V. Fuster,et al.  A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. , 1982, The New England journal of medicine.

[27]  C. Patrono,et al.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. , 1982, The Journal of clinical investigation.

[28]  G. Galanti,et al.  Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. , 1982, The American journal of cardiology.

[29]  C. Dollery,et al.  Prostacyclin is not a circulating hormone in man. , 1982, Prostaglandins.

[30]  W. Siess,et al.  Very low levels of 6-keto-prostaglandin F1 alpha in human plasma. , 1982, The Journal of laboratory and clinical medicine.

[31]  M. Inoue,et al.  Elevation of Thromboxane B2 Levels in Patients with Classic and Variant Angina Pectoris , 1981, Circulation.

[32]  J. Oates,et al.  Estimated rate of prostacyclin secretion into the circulation of normal man. , 1981, The Journal of clinical investigation.

[33]  R. Haslam,et al.  Measurement of circulating prostacyclin , 1981, Nature.

[34]  G. FitzGerald,et al.  Thromboxane A2 in Vasotonic Angina Pectoris , 1981 .

[35]  O. Ylikorkala,et al.  Measurement of 6-keto-prostaglandin F1α in human plasma with radioimmunoassay: Effect of prostacyclin infusion , 1981 .

[36]  L. Hillis,et al.  Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.

[37]  J. Frölich,et al.  Prostacyclin metabolites in human plasma , 1981, Clinical pharmacology and therapeutics.

[38]  K. Kaplan,et al.  Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo , 1981 .

[39]  M. Moskowitz,et al.  Platelet-dependent stimulation of prostacyclin synthesis by platelet-derived growth factor , 1980, Nature.

[40]  M. Carrara,et al.  PGI2-specific antibodies administered in vivo suggest against a role for endogenous PGI2 as a circulating vasodepressor hormone in the normotensive and spontaneously hypertensive rat. , 1980, Prostaglandins.

[41]  C. Patrono,et al.  Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. , 1980, Thrombosis research.

[42]  C. Dollery,et al.  PRODUCTION OF 6-OXO-PGF1α BY HUMAN LUNG IN VIVO , 1979, The Lancet.

[43]  P. Majerus,et al.  Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. , 1979, The New England journal of medicine.

[44]  H. Sinzinger,et al.  PROSTACYCLIN GENERATION IN ATHEROSCLEROTIC ARTERIES , 1979, The Lancet.

[45]  E. Jaffe,et al.  Recovery of endothelial cell prostacyclin production after inhibition by low doses of aspirin. , 1979, The Journal of clinical investigation.

[46]  E. Jaffe,et al.  Stimulation of endothelial cell prostacyclin production by thrombin, trypsin, and the ionophore A 23187. , 1978, The Journal of clinical investigation.

[47]  M. Mitchell,et al.  A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations. , 1978, Prostaglandins and medicine.

[48]  A. M. Lefer,et al.  Antibodies which antagonise the effects of prostacyclin , 1978, Nature.

[49]  J. Vane,et al.  Prostacyclin is a circulating hormone , 1978, Nature.

[50]  R. Gryglewski,et al.  Generation of prostacyclin by lungs in vivo and its release into the arterial circulation , 1978, Nature.

[51]  J. Vane,et al.  Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. , 1978, British medical bulletin.

[52]  P. Majerus,et al.  Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. , 1977, Biochemical and biophysical research communications.

[53]  R. Hardy,et al.  Controlled Trial of Aspirin in Cerebral Ischemia , 1977, Stroke.

[54]  J. Vane,et al.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. , 1976, Prostaglandins.

[55]  M. Hamberg,et al.  Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[56]  A. Busuttil,et al.  POLYPLOIDAL GIANT CELLS IN A LARYNGEAL BIOPSY , 1974 .

[57]  R. Gatti,et al.  Graft treatment of immunological deficiency. , 1969, Lancet.

[58]  M. Kumlin,et al.  Monitoring thromboxane production in vivo: metabolic and analytical aspects. , 1985, Advances in prostaglandin, thromboxane, and leukotriene research.

[59]  M. Yamagishi,et al.  Determination of plasma thromboxane B2 by radioimmunoassay: methodological problems and accuracy. , 1985, Advances in prostaglandin, thromboxane, and leukotriene research.

[60]  A. Náray-Fejes-Tóth,et al.  Analysis of prostanoid metabolites by gas chromatography/mass spectrometry. , 1985, Advances in prostaglandin, thromboxane, and leukotriene research.

[61]  F. ten Hoor,et al.  Prostacyclin production and atherosclerosis of the rabbit aorta. , 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

[62]  C. Patrono,et al.  Evidence for a direct stimulatory effect of prostacyclin on renin release in man. , 1982, The Journal of clinical investigation.

[63]  G. Galanti,et al.  Release of prostacyclin into the bloodstream and its exhaustion in humans after local blood flow changes (ischemia and venous stasis). , 1980, Thrombosis research.

[64]  E. Christ-Hazelhof,et al.  Determination of Nanogram Quantities of Eicosanoids as their Pentafluorobenzyl Derivatives by Gas Chromatography with Electron-Capture Detection , 1980 .